Codelivery of envelope protein in alum with MVA vaccine induces CXCR3- biased CXCR5+ and CXCR5- CD4 T cell responses in rhesus macaques

Smita Iyer, Sailaja Gangadhara, Blandine Victor, Rosy Gomez, Rahul Basu, Jung Joo Hong, Celia Labranche, David C. Montefiori, Francois Villinger, Bernard Moss, Rama Rao Amara

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The goal of an HIV vaccine is to generate robust and durable protective Ab. Vital to this goal is the induction of CD4+ T follicular helper (TFH) cells. However, very little is known about the TFH response to HIV vaccination and its relative contribution to magnitude and quality of vaccine-elicited Ab titers. In this study, we investigated these questions in the context of a DNA/modified vaccinia virus Ankara SIV vaccine with and without gp140 boost in aluminum hydroxide in rhesus macaques. In addition, we determined the frequency of vaccine-induced CD4+ T cells coexpressing chemokine receptor, CXCR5 (facilitates migration to B cell follicles) in blood and whether these responses were representative of lymph node TFH responses. We show that booster modified vaccinia virus Ankara immunization induced a distinct and transient accumulation of proliferating CXCR5+ and CXCR5- CD4 T cells in blood at day 7 postimmunization, and the frequency of the former but not the latter correlated with TFH and B cell responses in germinal centers of the lymph node. Interestingly, gp140 boost induced a skewing toward CXCR3 expression on germinal center TFH cells, which was strongly associated with longevity, avidity, and neutralization potential of vaccine-elicited Ab response. However, CXCR3+ cells preferentially expressed the HIV coreceptor CCR5, and vaccine-induced CXCR3+CXCR5+ cells showed a moderate positive association with peak viremia following SIV251 infection. Taken together, our findings demonstrate that vaccine regimens that elicit CXCR3-biased TFH cell responses favor Ab persistence and avidity but may predispose to higher acute viremia in the event of breakthrough infections.

Original languageEnglish (US)
Pages (from-to)994-1005
Number of pages12
JournalJournal of Immunology
Volume195
Issue number3
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Macaca mulatta
Helper-Inducer T-Lymphocytes
Vaccines
T-Lymphocytes
Germinal Center
Vaccinia virus
Viremia
Proteins
SAIDS Vaccines
B-Lymphocytes
Lymph Nodes
HIV
Aluminum Hydroxide
AIDS Vaccines
Chemokine Receptors
Infection
Immunization
Vaccination
MVA vaccine
aluminum sulfate

ASJC Scopus subject areas

  • Immunology

Cite this

Codelivery of envelope protein in alum with MVA vaccine induces CXCR3- biased CXCR5+ and CXCR5- CD4 T cell responses in rhesus macaques. / Iyer, Smita; Gangadhara, Sailaja; Victor, Blandine; Gomez, Rosy; Basu, Rahul; Hong, Jung Joo; Labranche, Celia; Montefiori, David C.; Villinger, Francois; Moss, Bernard; Amara, Rama Rao.

In: Journal of Immunology, Vol. 195, No. 3, 01.01.2015, p. 994-1005.

Research output: Contribution to journalArticle

Iyer, S, Gangadhara, S, Victor, B, Gomez, R, Basu, R, Hong, JJ, Labranche, C, Montefiori, DC, Villinger, F, Moss, B & Amara, RR 2015, 'Codelivery of envelope protein in alum with MVA vaccine induces CXCR3- biased CXCR5+ and CXCR5- CD4 T cell responses in rhesus macaques', Journal of Immunology, vol. 195, no. 3, pp. 994-1005. https://doi.org/10.4049/jimmunol.1500083
Iyer, Smita ; Gangadhara, Sailaja ; Victor, Blandine ; Gomez, Rosy ; Basu, Rahul ; Hong, Jung Joo ; Labranche, Celia ; Montefiori, David C. ; Villinger, Francois ; Moss, Bernard ; Amara, Rama Rao. / Codelivery of envelope protein in alum with MVA vaccine induces CXCR3- biased CXCR5+ and CXCR5- CD4 T cell responses in rhesus macaques. In: Journal of Immunology. 2015 ; Vol. 195, No. 3. pp. 994-1005.
@article{f9ce347c7ccb46aeaf20cd8f4b3742b1,
title = "Codelivery of envelope protein in alum with MVA vaccine induces CXCR3- biased CXCR5+ and CXCR5- CD4 T cell responses in rhesus macaques",
abstract = "The goal of an HIV vaccine is to generate robust and durable protective Ab. Vital to this goal is the induction of CD4+ T follicular helper (TFH) cells. However, very little is known about the TFH response to HIV vaccination and its relative contribution to magnitude and quality of vaccine-elicited Ab titers. In this study, we investigated these questions in the context of a DNA/modified vaccinia virus Ankara SIV vaccine with and without gp140 boost in aluminum hydroxide in rhesus macaques. In addition, we determined the frequency of vaccine-induced CD4+ T cells coexpressing chemokine receptor, CXCR5 (facilitates migration to B cell follicles) in blood and whether these responses were representative of lymph node TFH responses. We show that booster modified vaccinia virus Ankara immunization induced a distinct and transient accumulation of proliferating CXCR5+ and CXCR5- CD4 T cells in blood at day 7 postimmunization, and the frequency of the former but not the latter correlated with TFH and B cell responses in germinal centers of the lymph node. Interestingly, gp140 boost induced a skewing toward CXCR3 expression on germinal center TFH cells, which was strongly associated with longevity, avidity, and neutralization potential of vaccine-elicited Ab response. However, CXCR3+ cells preferentially expressed the HIV coreceptor CCR5, and vaccine-induced CXCR3+CXCR5+ cells showed a moderate positive association with peak viremia following SIV251 infection. Taken together, our findings demonstrate that vaccine regimens that elicit CXCR3-biased TFH cell responses favor Ab persistence and avidity but may predispose to higher acute viremia in the event of breakthrough infections.",
author = "Smita Iyer and Sailaja Gangadhara and Blandine Victor and Rosy Gomez and Rahul Basu and Hong, {Jung Joo} and Celia Labranche and Montefiori, {David C.} and Francois Villinger and Bernard Moss and Amara, {Rama Rao}",
year = "2015",
month = "1",
day = "1",
doi = "10.4049/jimmunol.1500083",
language = "English (US)",
volume = "195",
pages = "994--1005",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "3",

}

TY - JOUR

T1 - Codelivery of envelope protein in alum with MVA vaccine induces CXCR3- biased CXCR5+ and CXCR5- CD4 T cell responses in rhesus macaques

AU - Iyer, Smita

AU - Gangadhara, Sailaja

AU - Victor, Blandine

AU - Gomez, Rosy

AU - Basu, Rahul

AU - Hong, Jung Joo

AU - Labranche, Celia

AU - Montefiori, David C.

AU - Villinger, Francois

AU - Moss, Bernard

AU - Amara, Rama Rao

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The goal of an HIV vaccine is to generate robust and durable protective Ab. Vital to this goal is the induction of CD4+ T follicular helper (TFH) cells. However, very little is known about the TFH response to HIV vaccination and its relative contribution to magnitude and quality of vaccine-elicited Ab titers. In this study, we investigated these questions in the context of a DNA/modified vaccinia virus Ankara SIV vaccine with and without gp140 boost in aluminum hydroxide in rhesus macaques. In addition, we determined the frequency of vaccine-induced CD4+ T cells coexpressing chemokine receptor, CXCR5 (facilitates migration to B cell follicles) in blood and whether these responses were representative of lymph node TFH responses. We show that booster modified vaccinia virus Ankara immunization induced a distinct and transient accumulation of proliferating CXCR5+ and CXCR5- CD4 T cells in blood at day 7 postimmunization, and the frequency of the former but not the latter correlated with TFH and B cell responses in germinal centers of the lymph node. Interestingly, gp140 boost induced a skewing toward CXCR3 expression on germinal center TFH cells, which was strongly associated with longevity, avidity, and neutralization potential of vaccine-elicited Ab response. However, CXCR3+ cells preferentially expressed the HIV coreceptor CCR5, and vaccine-induced CXCR3+CXCR5+ cells showed a moderate positive association with peak viremia following SIV251 infection. Taken together, our findings demonstrate that vaccine regimens that elicit CXCR3-biased TFH cell responses favor Ab persistence and avidity but may predispose to higher acute viremia in the event of breakthrough infections.

AB - The goal of an HIV vaccine is to generate robust and durable protective Ab. Vital to this goal is the induction of CD4+ T follicular helper (TFH) cells. However, very little is known about the TFH response to HIV vaccination and its relative contribution to magnitude and quality of vaccine-elicited Ab titers. In this study, we investigated these questions in the context of a DNA/modified vaccinia virus Ankara SIV vaccine with and without gp140 boost in aluminum hydroxide in rhesus macaques. In addition, we determined the frequency of vaccine-induced CD4+ T cells coexpressing chemokine receptor, CXCR5 (facilitates migration to B cell follicles) in blood and whether these responses were representative of lymph node TFH responses. We show that booster modified vaccinia virus Ankara immunization induced a distinct and transient accumulation of proliferating CXCR5+ and CXCR5- CD4 T cells in blood at day 7 postimmunization, and the frequency of the former but not the latter correlated with TFH and B cell responses in germinal centers of the lymph node. Interestingly, gp140 boost induced a skewing toward CXCR3 expression on germinal center TFH cells, which was strongly associated with longevity, avidity, and neutralization potential of vaccine-elicited Ab response. However, CXCR3+ cells preferentially expressed the HIV coreceptor CCR5, and vaccine-induced CXCR3+CXCR5+ cells showed a moderate positive association with peak viremia following SIV251 infection. Taken together, our findings demonstrate that vaccine regimens that elicit CXCR3-biased TFH cell responses favor Ab persistence and avidity but may predispose to higher acute viremia in the event of breakthrough infections.

UR - http://www.scopus.com/inward/record.url?scp=84937711740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937711740&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1500083

DO - 10.4049/jimmunol.1500083

M3 - Article

C2 - 26116502

AN - SCOPUS:84937711740

VL - 195

SP - 994

EP - 1005

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 3

ER -